Exicure, Inc. Releases Full Year 2025 Financial Results: Key Updates for Investors

Overview

Exicure, Inc. (Nasdaq: XCUR), a biotechnology company in transition, has published its unaudited financial results for the year ended December 31, 2025. The report details significant changes in the company’s operations, financial position, and strategic direction following the acquisition of GPCR Therapeutics USA Inc. (“GPCR USA”) in January 2025. The company is currently exploring strategic alternatives after a major restructuring and the suspension of its previous clinical and development activities.

Key Financial Highlights

• Cash Position: Cash and cash equivalents stood at \$3.7 million at the end of 2025, a sharp decrease from \$12.5 million at the end of 2024. The company warns that its liquidity may not be sufficient to fund operations for the next 12 months, making additional financing an urgent need.
• Research & Development (R&D) Expenses: R&D expenses rose to \$3.3 million in 2025 from \$0 in 2024. This increase is attributed to R&D activities initiated after acquiring GPCR USA, which conducts research operations. Prior to this acquisition, Exicure had suspended all such expenses.
• General & Administrative (G&A) Expenses: G&A expenses increased to \$6.8 million in 2025 from \$5.4 million in 2024. The \$1.4 million rise was driven primarily by costs associated with the acquisition and integration of GPCR USA.
• Net Loss: The company reported a net loss of \$4.9 million for 2025, a significant improvement from the \$9.7 million net loss in 2024. This decrease is primarily due to a \$6.0 million gain from the early termination of its Chicago office lease, which offset increased operating expenses post-acquisition.

Other Significant Financial Items

• Loss from Asset Sales: Exicure recognized a \$90,000 loss from the sale of GPCR USA’s fixed assets.
• Gain on Early Lease Termination: The \$6.0 million gain resulted from the reversal of the remaining liability on the terminated Chicago office lease, effective January 31, 2025.
• Other Income/Expense: The company realized a \$346,000 gain from satisfying its self-insured retention with its insurer, a \$1.6 million loss from changes in the fair value of a contingent liability, and a \$275,000 loss related to the sale of its subsidiary, KC Creation, along with currency translation losses.

Balance Sheet Summary

• Total Assets: \$14.0 million as of December 31, 2025, compared to \$15.1 million at year-end 2024.
• Total Liabilities: \$10.1 million, up from \$8.3 million in 2024, reflecting increased contingent liabilities and deferred tax liability post-acquisition.
• Stockholders’ Equity: \$3.9 million, a decrease from \$6.8 million in 2024.
• Goodwill and Intangibles: Goodwill of \$4.4 million and intangible assets of \$3.8 million were recorded in 2025 following the acquisition of GPCR USA.

Operational and Strategic Updates

• Acquisition of GPCR USA: In January 2025, Exicure acquired GPCR USA, a clinical-stage biotech company developing therapeutics for hematologic diseases. The lead program is being evaluated for stem cell mobilization in multiple myeloma, sickle cell disease, and as a support for cell and gene therapy programs.
• Strategic Alternatives: The company is actively exploring strategic alternatives to maximize shareholder value after suspending its original clinical programs and restructuring operations. This includes potential further cost reductions, although management notes the ability to cut costs further is limited.
• Going Concern Warning: Exicure’s management has issued a clear warning that the company’s current cash reserves are not sufficient to fund ongoing operations. Substantial additional financing is required in the short term to pay expenses, support strategic exploration, and fund operations. There is no assurance that additional financing will be available or available on acceptable terms.

Potential Share Price Sensitivities

• Liquidity Crisis: The company’s admission that it may not have enough cash to continue operations without immediate financing is highly price-sensitive and may weigh on the share price if suitable funding is not secured soon.
• Strategic Transactions: Any future strategic alternatives, including potential mergers, acquisitions, or asset sales, could move the share price significantly depending on their nature and terms.
• Operational Turnaround: The integration of GPCR USA and the progress of its lead program in hematologic diseases could offer upside if positive data or partnerships are announced. However, current uncertainty and funding risks dominate the outlook.

Forward-Looking Statements and Risks

The company has emphasized that its forward-looking statements are subject to significant risks, including the uncertainty of additional equity investments, the results of the ongoing Nasdaq listing process, and the outcome of the company’s strategic review. Investors are urged to consider the risk factors detailed in Exicure’s filings with the SEC.

Conclusion

Exicure faces a critical juncture: with minimal cash reserves and new strategic directions post-acquisition, the company’s immediate future hinges on securing further financing and making successful strategic decisions. The continued exploration of alternatives and the fate of its new hematology program will be closely watched by investors and could have a material impact on share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should consult with their financial advisors before making investment decisions. All forward-looking statements are subject to risks and uncertainties as outlined in the company’s public filings.

View EXICURE, INC. Historical chart here